Nephrology Dialysis Transplantation, Vol 14, Issue 90002 85-92, Copyright © 1999 by Oxford University Press
H Ludwig
Cancer-related anaemia has a number of causes, not least The underlying
malignancy itself which plays a role in suppressing erythropoiesis. Anaemia
is often exacerbated by cancer treatments, in particular routinely used
cytotoxic chemotherapy. Chronic anaemia of cancer is characterized by
inappropriately low levels of endogenous erythropoietin for The degree of
anaemia, and manifests clinically with generalized hypoxia and resultant
severe fatigue. Epoetin alfa is one recombinant form of erythropoietin, The
primary human growth factor responsible for promoting proliferation and
survival of erythroid progenitor cells. Epoetin alfa has been widely
studied for The treatment of anaemia associated with renal failure and is
now recognized as having significant potential in The management of
cancer-related anaemia. Studies suggest that epoetin alfa is an effective
treatment in a proportion of cancer patients with symptomatic anaemia. It
also appears useful for The prevention of chemotherapy-induced anaemia.
Studies in a number of different cancer settings have shown that epoetin
alfa significantly increases haemoglobin and haematocrit, reduces
transfusion requirements and improves quality of life for The patient.
Keywords: anaemia; cancer; epoetin; fatigue;
haemoglobin; quality of life
ORIGINAL ARTICLES
Epoetin in cancer-related anaemia
First Department of Medicine and Medical Oncology, Wilhelminenspital, Montlearstrasse 37, A-1171 Vienna 16, Austria
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujisaka, T. Tamura, Y. Ohe, H. Kunitoh, I. Sekine, N. Yamamoto, H. Nokihara, A. Horiike, T. Kodama, and N. Saijo Pharmacokinetics and Pharmacodynamics of Weekly Epoetin Beta in Lung Cancer Patients Jpn. J. Clin. Oncol., August 1, 2006; 36(8): 477 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Gordon Managing Anemia in the Cancer Patient: Old Problems, Future Solutions Oncologist, August 1, 2002; 7(4): 331 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Zaidi and D. H. Vesole Multiple Myeloma: An Old Disease with New Hope for the Future CA Cancer J Clin, September 1, 2001; 51(5): 273 - 285. [Abstract] [Full Text] [PDF]
|
|